Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).
In Gyu Hwang
No relevant relationships to disclose
Jung Hun Kang
No relevant relationships to disclose
Soonil Lee
No relevant relationships to disclose
Hyo Rak Lee
No relevant relationships to disclose
Hui Young Lee
No relevant relationships to disclose
Jun Ho Ji
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Se Hoon Park
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Ho Yeong Lim
No relevant relationships to disclose
Won Ki Kang
No relevant relationships to disclose